

Award Number: W81XWH-18-2-0024

TITLE: Abbreviated Magnetic Resonance Imaging and Biomarker-Based Detection of Early Liver Cancer

PRINCIPAL INVESTIGATOR: Dr. Robert Marks

CONTRACTING ORGANIZATION:

The Henry M. Jackson Foundation
for the Advancement of Military Medicine
6720-A Rockledge Drive
Bethesda, MD 20817

REPORT DATE: OCTOBER 2020

TYPE OF REPORT: Annual

PREPARED FOR: U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT:

Approved for public release; distribution unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

REPORT DOCUMENTATION PAGEForm Approved
OMB No. 0704-0188

Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Department of Defense, Washington Headquarters Services, Directorate for Information Operations and Reports (0704-0188), 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302. Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to any penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number. **PLEASE DO NOT RETURN YOUR FORM TO THE ABOVE ADDRESS.**

1. REPORT DATE (DD-MM-YYYY) OCTOBER 2020		2. REPORT TYPE Annual	3. DATES COVERED (From - To) 9/30/19 - 9/29/20		
4. TITLE AND SUBTITLE Abbreviated Magnetic Resonance Imaging and Biomarker-Based Detection of Early Liver Cancer			5a. CONTRACT NUMBER		
			5b. GRANT NUMBER W81XWH-18-2-0024		
			5c. PROGRAM ELEMENT NUMBER		
6. AUTHOR(S) Dr. Robert Marks			5d. PROJECT NUMBER		
			5e. TASK NUMBER		
			5f. WORK UNIT NUMBER		
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) Henry M. Jackson Foundation 6720-A Rockledge Drive Bethesda, MD 20817			8. PERFORMING ORGANIZATION REPORT NUMBER		
9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) CDMRP U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012			10. SPONSOR/MONITOR'S ACRONYM(S)		
			11. SPONSOR/MONITOR'S REPORT NUMBER(S)		
12. DISTRIBUTION / AVAILABILITY STATEMENT Approved for public release; distribution unlimited					
13. SUPPLEMENTARY NOTES					
14. ABSTRACT Hepatocellular carcinoma (HCC) is the second leading cause of cancer-related death worldwide and is the fastest growing cause of cancer death in the United States. Current national guidelines recommend surveillance of all patients at risk for HCC with a lab draw and an Ultrasound (US) examination every 6 months. However, many studies have shown that Ultrasound's ability to detect cancer reliably, especially small tumors, is poor. Many centers in the United States perform contrast-enhanced magnetic resonance imaging (MRI) for HCC surveillance as it has been shown to be more accurate in the detection of HCC than US. However, complete contrast-enhanced MRI is too expensive to be considered a first line surveillance examination. We previously simulated and studied a novel abbreviated MRI (AMRI) protocol, using a unique intravenous contrast agent used for liver MRIs that takes approximately 10 minutes to complete. We found that the accuracy of the AMRI protocol was 20% better than that of US. We have shown that in moderate to high-risk groups, AMRI is more cost effective than US. We now seek to fill remaining gaps by rigorously comparing the performance of AMRI vs. US for HCC screening in a large prospectively assembled cohort of subjects at risk for HCC; assessing the added diagnostic value of clinical biomarkers (AFP, AFP-L3, DCP) and other clinical variables; examine the cost effectiveness of AMRI, US, and of each imaging method in combination with clinical biomarkers; and bank biospecimens for future biomarker discovery studies.					
15. SUBJECT TERMS AMRI hepatocellular carcinoma liver cancer					
16. SECURITY CLASSIFICATION OF:			17. LIMITATION OF ABSTRACT	18. NUMBER OF PAGES	19a. NAME OF RESPONSIBLE PERSON
a. REPORT	b. ABSTRACT	c. THIS PAGE			19b. TELEPHONE NUMBER (include area code)
U	U	U	UU	5	USAMRMC

Table of Contents

	<u>Page</u>
Introduction.....	1
Body.....	1
Key Research Accomplishments.....	1
Reportable Outcomes.....	2
Conclusion.....	2
References.....	2
Appendices.....	2

Introduction

Hepatocellular carcinoma (HCC) is the second leading cause of cancer-related death worldwide and is the fastest growing cause of cancer death in the United States. Current national guidelines recommend surveillance of all patients at risk for HCC with a lab draw and an Ultrasound (US) examination every 6 months. However, many studies have shown that Ultrasound's ability to detect cancer reliably, especially small tumors, is poor. Many centers in the United States perform contrast-enhanced magnetic resonance imaging (MRI) for HCC surveillance as it has been shown to be more accurate in the detection of HCC than US. However, complete contrast-enhanced MRI is too expensive to be considered a first line surveillance examination. We previously simulated and studied a novel abbreviated MRI (AMRI) protocol, using a unique intravenous contrast agent used for liver MRIs that takes approximately 10 minutes to complete. We found that the accuracy of the AMRI protocol was 20% better than that of US. We have shown that in moderate to high-risk groups, AMRI is more cost effective than US. We now seek to fill remaining gaps by rigorously comparing the performance of AMRI vs. US for HCC screening in a large prospectively assembled cohort of subjects at risk for HCC; assessing the added diagnostic value of clinical biomarkers (AFP, AFP-L3, DCP) and other clinical variables; examine the cost effectiveness of AMRI, US, and of each imaging method in combination with clinical biomarkers; and bank biospecimens for future biomarker discovery studies.

Body

Recruited 37 patients with cirrhosis or cHBV. One patient was a screen fail, one patient was lost to follow up and two patients voluntarily withdrew from the study.

Due to COVID-19, several patient appointments in March, April and May were canceled. Additionally, patient recruitment and enrollment has also been severely affected by the pandemic. Enrollment and study appointments resumed in June, however because of the continued pandemic, enrollment has been slower than anticipated as patients are not being seen as often in the Gastroenterology department.

Key Research Accomplishment

- A total of 37 patients have been enrolled into the study.
- A total of 31 patients have completed their clinic visit at UCSD.
- Total of 29 patients have completed their imaging visits.
- A total of 29 study patients have completed all study components. Their imaging data has been interpreted.
- Patient images have been de-identified for analysis

Reportable Outcomes - Provide a list of reportable outcomes that have resulted from this research to include manuscripts, abstracts, presentations, etc.

No reportable outcomes to report.

Conclusion

Study enrollment has been steady, although it has slowed down during the pandemic, with a total of 36 patients enrolled since April 10, 2019. A total of 29 patients have completed all study visits and their images have been interpreted. The research team is actively screening patients for study participation. Plans for the upcoming year is to complete enrollment and study visits for all patients. In addition, complete the analysis of images.

References - List any references using standard journal format.

No references to report.

Appendices - Can include copies of journal articles, manuscripts and abstracts, patent applications, study questionnaires and surveys, etc.

No appendices to report.